Antibody therapeutics are usually developed in animals, commonly in mouse, and then they are humanized by Complementary-Determining Regions (CDR) grafting. Several times, this key step fails because of the lack of stability and/or functionality of the new antibody and the immunogenicity. Different efforts have been made to improve the humanization; many of them rely on the quantification of the humanness of the variable region. Previous researches have reported a statistical approach based on a Multivariate Gaussian (MG) model which successfully distinguishes between human and murine sequences. However, the strength and weaknesses of this model have not be properly studied yet, and a full understanding of where its efficacy comes from, and...
In this work, we propose a model for the structure of the antigen-antibody complex formed by human H...
Immunodominant T cell epitopes preferentially targeted in multiple individuals are the critical elem...
MOTIVATION: The precise targeting of antibodies and other protein therapeutics is required for their...
Abstract Antibody humanization is a key step in the preclinical phase of the development of therapeu...
Motivation: Monoclonal antibody therapeutics are often produced from non-human sources (typically mu...
Antibodies - key molecules of the immune system - are increasingly used as ther- apeutic drugs. The ...
<div><p>1-17-2 is a rat anti-human DEC-205 monoclonal antibody that induces internalization and deli...
Despite their utility as models for human systems, intrinsic differences between mouse and human bio...
Chimeric, humanized and human antibodies have successively been exploited as therapeutics because th...
The high failure rate of therapeutics showing promise in mouse models to translate to patients is a ...
The high failure rate of therapeutics showing promise in mouse models to translate to patients is a ...
Although antibody affinity is primarily determined by immunoglobulin variable region structure human...
The structural and dynamic changes introduced during antibody humanization continue to be a topic op...
In this work, we propose a model for the structure of the antigen-antibody complex formed by human H...
Therapeutic antibodies are widely used for disease detection and specific treatments. However, as an...
In this work, we propose a model for the structure of the antigen-antibody complex formed by human H...
Immunodominant T cell epitopes preferentially targeted in multiple individuals are the critical elem...
MOTIVATION: The precise targeting of antibodies and other protein therapeutics is required for their...
Abstract Antibody humanization is a key step in the preclinical phase of the development of therapeu...
Motivation: Monoclonal antibody therapeutics are often produced from non-human sources (typically mu...
Antibodies - key molecules of the immune system - are increasingly used as ther- apeutic drugs. The ...
<div><p>1-17-2 is a rat anti-human DEC-205 monoclonal antibody that induces internalization and deli...
Despite their utility as models for human systems, intrinsic differences between mouse and human bio...
Chimeric, humanized and human antibodies have successively been exploited as therapeutics because th...
The high failure rate of therapeutics showing promise in mouse models to translate to patients is a ...
The high failure rate of therapeutics showing promise in mouse models to translate to patients is a ...
Although antibody affinity is primarily determined by immunoglobulin variable region structure human...
The structural and dynamic changes introduced during antibody humanization continue to be a topic op...
In this work, we propose a model for the structure of the antigen-antibody complex formed by human H...
Therapeutic antibodies are widely used for disease detection and specific treatments. However, as an...
In this work, we propose a model for the structure of the antigen-antibody complex formed by human H...
Immunodominant T cell epitopes preferentially targeted in multiple individuals are the critical elem...
MOTIVATION: The precise targeting of antibodies and other protein therapeutics is required for their...